191
Participants
Start Date
April 21, 2016
Primary Completion Date
December 2, 2019
Study Completion Date
January 5, 2021
Placebo for maraviroc (MVC)
Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
Placebo for dolutegravir (DTG)
Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
Dolutegravir (DTG)
Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
Maraviroc (MVC)
Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
Wits Helen Joseph Hospital CRS (Wits HJH CRS), Johannesburg
Durban International Clinical Research Site CRS, Durban
Famcru Crs, Tygerberg
Weill Cornell Chelsea CRS, New York
Weill Cornell Uptown CRS, New York
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS, Bangkok
University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester
University of Pittsburgh CRS, Pittsburgh
Penn Therapeutics, CRS, Philadelphia
Whitman-Walker Health CRS, Washington D.C.
Johns Hopkins University CRS, Baltimore
Greensboro CRS, Greensboro
Chapel Hill CRS, Chapel Hill
Vanderbilt Therapeutics (VT) CRS, Nashville
Ohio State University CRS, Columbus
Case Clinical Research Site, Cleveland
Cincinnati Clinical Research Site, Cincinnati
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai
Northwestern University CRS, Chicago
Trinity Health and Wellness Center CRS, Dallas
Houston AIDS Research Team CRS, Houston
UCLA CARE Center CRS, Los Angeles
Harbor-UCLA CRS, Torrance
UCSD Antiviral Research Center CRS, San Diego
Washington University Therapeutics (WT) CRS, St Louis
New Jersey Medical School Clinical Research Center CRS, Newark
The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence
University of Washington AIDS CRS, Seattle
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro
Puerto Rico AIDS Clinical Trials Unit CRS, San Juan
National Institute of Allergy and Infectious Diseases (NIAID)
NIH